AR080585A1 - Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias - Google Patents

Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias

Info

Publication number
AR080585A1
AR080585A1 ARP110100809A ARP110100809A AR080585A1 AR 080585 A1 AR080585 A1 AR 080585A1 AR P110100809 A ARP110100809 A AR P110100809A AR P110100809 A ARP110100809 A AR P110100809A AR 080585 A1 AR080585 A1 AR 080585A1
Authority
AR
Argentina
Prior art keywords
tumor
protein
tumors
antigen
proteins
Prior art date
Application number
ARP110100809A
Other languages
English (en)
Inventor
Thomas Hiller
Jens Schumacher
Thorsten Klamp
Ugur Sahin
Ozlem Tureci
Michael Koslowski
Original Assignee
Universitaetsmedizin Der Johannes Gutenberg Uni Mainz
Biontech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10002775A external-priority patent/EP2366709A1/en
Application filed by Universitaetsmedizin Der Johannes Gutenberg Uni Mainz, Biontech Ag filed Critical Universitaetsmedizin Der Johannes Gutenberg Uni Mainz
Publication of AR080585A1 publication Critical patent/AR080585A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se relaciona con la inmunoterapia de los tumores, particularmente con la vacunacion contra los tumores, mediante el uso de proteínas quiméricas que comprenden la totalidad o una porcion de la proteína antigénica principal del virus de la hepatitis B y una secuencia de aminoácidos que comprende un epítope derivado de una porcion extracelular de un antígeno asociado a un tumor. En particular, se proveen partículas similares a virus que comprenden dichas proteínas quiméricas para provocar una respuesta inmune humoral en un sujeto contra el antígeno asociado al tumor, particularmente contra las células que contienen dicho antígeno asociado a un tumor en su superficie, donde el antígeno asociado al tumor es una proteína propia de dicho sujeto. Proteína. Vector. Acido nucleico. Composicion inmunologica. Reivindicacion 3: La proteína de la reivindicacion 1 o 2, caracterizada porque el antígeno asociado al tumor es una proteína de la familia de la claudina o PLAC1, donde la proteína de la familia de la claudina preferiblemente se selecciona del grupo que consiste en CLDN18.2 y CLDN6.
ARP110100809A 2010-03-16 2011-03-14 Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias AR080585A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10002775A EP2366709A1 (en) 2010-03-16 2010-03-16 Tumor vaccination involving a humoral immune response against self-proteins
EP10016216 2010-12-30

Publications (1)

Publication Number Publication Date
AR080585A1 true AR080585A1 (es) 2012-04-18

Family

ID=43855962

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100809A AR080585A1 (es) 2010-03-16 2011-03-14 Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias

Country Status (9)

Country Link
US (3) US8840902B2 (es)
EP (1) EP2547695B1 (es)
JP (2) JP6199036B2 (es)
AR (1) AR080585A1 (es)
AU (1) AU2011229518B2 (es)
CA (1) CA2786940C (es)
ES (1) ES2675825T3 (es)
TR (1) TR201809413T4 (es)
WO (1) WO2011113546A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CA2786940C (en) 2010-03-16 2019-09-24 Biontech Ag Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
UA128182C2 (uk) 2012-11-13 2024-05-01 Біонтех Аґ Агенти для лікування експресуючих клаудин ракових захворювань
PL3708579T3 (pl) * 2014-04-01 2024-08-05 Biontech Cell & Gene Therapies Gmbh Immunoreceptory specyficzne dla klaudyny-6 i epitopy komórek t
CN104293741A (zh) * 2014-10-10 2015-01-21 武汉大学 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
AU2018240421A1 (en) * 2017-03-24 2019-09-26 BioNTech SE Methods and compositions for stimulating immune response
BR112020015479A2 (pt) 2018-03-08 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anticlaudina 18.2 e usos dos mesmos
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
CN114560941B (zh) * 2020-11-27 2024-01-16 广东东阳光药业股份有限公司 Cldn18.2的抗体及其应用
CN114836388A (zh) * 2022-06-07 2022-08-02 江苏亲科生物研究中心有限公司 Claudin18.2单克隆抗体及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU2540897A (en) * 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
PT1268530E (pt) * 2000-04-07 2006-12-29 Univ Leeds Proteínas de fusão do antigénio do core da hepatite b
AU2002339224B2 (en) * 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR20050115913A (ko) 2003-03-26 2005-12-08 사이토스 바이오테크놀로지 아게 Ｍｅｌａｎ―ａ 펩티드 유사체-바이러스-양-입자컨쥬게이트
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US20110104191A1 (en) 2007-09-11 2011-05-05 Universite Laval Malva mosaic virus and virus-like particles and uses thereof
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
SG10201402493UA (en) * 2009-02-20 2014-10-30 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
CN101584860A (zh) * 2009-04-27 2009-11-25 西安杰诺瓦生物科技有限公司 重组人Claudin18.2肿瘤疫苗及其制备方法
CA2786940C (en) 2010-03-16 2019-09-24 Biontech Ag Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2

Also Published As

Publication number Publication date
US10526387B2 (en) 2020-01-07
US8840902B2 (en) 2014-09-23
AU2011229518B2 (en) 2015-09-24
US20150152154A1 (en) 2015-06-04
TR201809413T4 (tr) 2018-07-23
US20170072035A1 (en) 2017-03-16
US20130052217A1 (en) 2013-02-28
CA2786940C (en) 2019-09-24
JP2017025057A (ja) 2017-02-02
EP2547695A1 (en) 2013-01-23
JP6199036B2 (ja) 2017-09-20
JP2013521785A (ja) 2013-06-13
CA2786940A1 (en) 2011-09-22
ES2675825T3 (es) 2018-07-12
AU2011229518A1 (en) 2012-08-30
US9617321B2 (en) 2017-04-11
EP2547695B1 (en) 2018-05-09
WO2011113546A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
WO2010104749A3 (en) Antigen presenting cell targeted cancer vaccines
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
WO2017210579A8 (en) Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
EA201071297A1 (ru) Новые и действенные пептиды мнс ii класса, полученные из сурвивина
MX337397B (es) Vacunas anti-virales dirigidas a celulas que presentan antigeno.
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
EA201892735A1 (ru) Состав вакцины против hiv
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
MX2013013228A (es) Particulas similares a virus y proceso para prepararlas.
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
MX2019007924A (es) Vacunas contra la influenza.
MX2016009952A (es) Proteinas y antigenos del virus de diarrea epidemica porcino (pedv).

Legal Events

Date Code Title Description
FG Grant, registration